Review
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept
Affiliations
- PMID: 12851990
Item in Clipboard
Review
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept
J Drugs Dermatol.
2002 Dec.
Abstract
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
Similar articles
-
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2. Clin Ther. 2003. PMID: 14667953 Review.
-
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Br J Dermatol. 2008. PMID: 18547300 Review.
-
Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.J Drugs Dermatol. 2005 Sep-Oct;4(5):544-55. J Drugs Dermatol. 2005. PMID: 16167412 Review.
-
Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.Cutis. 2003 Jan;71(1):25-9. Cutis. 2003. PMID: 12553627 Review.
-
[New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].Ned Tijdschr Geneeskd. 2006 May 13;150(19):1065-70. Ned Tijdschr Geneeskd. 2006. PMID: 16733982 Review. Dutch.
Cited by
-
Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study.Drugs Aging. 2009;26(7):607-15. doi: 10.2165/11316350-000000000-00000. Drugs Aging. 2009. PMID: 19655827
-
Genetic, cellular and immune approaches to disease therapy: past and future.Nat Med. 2004 Feb;10(2):135-41. doi: 10.1038/nm990. Nat Med. 2004. PMID: 14760423 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical